Articles

Angie’s List stock falls after growth slows

Never mind that Angie’s List posts a loss every year. Wall Street isn’t worried about that, right now. But let its double-digit revenue growth slow just a bit and, before you know it, the stock has fallen 33 percent—as it did in October.

Read More

Lilly stock shrugs off analyst downgrade

The drugmaker has become too reliant on its remaining pipeline of drugs under development for growth as it deals with patent expirations to big sellers and drug-development setbacks, a Jefferies analyst wrote.

Read More

Indiana sues estate of alleged Ponzi schemer

The state has gone to court to freeze the assets of the estate of a dead Kokomo investment adviser so the money can provide possible restitution to victims of a Ponzi scheme who might include former National Football League players.

Read More

SEC accuses Indy cancer firm of being a sham

The SEC says the CEO of locally based biomedical firm Xytos Inc. has committed securities fraud
since 2010 by repeatedly publishing false information to investors about the company. Timothy Cook denies the accusations.

Read More